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In 1999, prevention of mother-to-child transmission (pMTCT) using antiretrovirals was introduced in the Dominican Republic
(DR). Highly active antiretroviral therapy (HAART) was introduced for immunosuppressed persons in 2004 and for pMTCT in
2008. To assess progress towards MTCT elimination, data from requisitions for HIV nucleic acid amplification tests for diagnosis
of HIV infection in perinatally exposed infants born in the DR from 1999 to 2011 were analyzed. The MTCT rate was 142/1,274
(11.1%) in 1999–2008 and 12/302 (4.0%) in 2009–2011 (P < .001), with a rate of 154/1,576 (9.8%) for both periods combined.
This decline was associated with significant increases in the proportions of women who received prenatal HAART (from 12.3% to
67.9%) and infants who received exclusive formula feeding (from 76.3% to 86.1%) and declines in proportions of women who
received no prenatal antiretrovirals (from 31.9% to 12.2%) or received only single-dose nevirapine (from 39.5% to 19.5%). In 2007,
over 95% of DR pregnant women received prenatal care, HIV testing, and professionally attended delivery. However, only 58% of
women in underserved sugarcane plantation communities (2007) and 76% in HIV sentinel surveillance hospitals (2003–2005)
received their HIV test results. HIV-MTCT elimination is feasible but persistent lack of access to critical pMTCTmeasures must be
addressed.
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1. Introduction
HIV mother-to-child transmission (MTCT) continues to
threaten child survival worldwide. Over two million children
are infected with HIV, the vast majority infected by MTCT
in low- and middle-income (LMI) countries [1, 2]. The
persistence of HIV MTCT underscores the importance of
increasing access to eﬀective prevention of MTCT (pMTCT)
strategies. Virtual elimination of HIV MTCT has been
achieved in most industrialized countries, with declines of
over 80%–90% in the number of cases of perinatally acquired
HIV infection, and MTCT rates of under 2%-3% [3–5]. The
use of highly active antiretroviral therapy ([HAART], defined
as a regimen of three or more antiretrovirals from two or
more classes), which is essential for elimination of MTCT
and contributes to maternal health, has been shown to be
cost eﬀective compared to single-dose nevirapine in several
LMI countries, including the Dominican Republic (DR) [6–
8], but few data exist on the scalability of these measures or
the current obstacles to eliminatingMTCT in these countries
[9–13].
The DR is home to 25% of persons living with HIV in
the Caribbean, the second highest HIV-prevalence region
in the world [1, 9, 10]. To assess progress towards MTCT
elimination in this MI country, we analyzed data recorded
at the time of collection of samples for virologic testing
performed to determine whether perinatally exposed infants
and young children had acquired HIV infection.
2. Methods
2.1. Population. Guardians of infants and children known
or suspected of being perinatally HIV-exposed were asked if
they would consent to diagnostic virologic testing of their
children as part of pediatric care. The population tested
included infants and children whosemothers were diagnosed
with HIV infection before or during pregnancy, at delivery,
and up to 25 months after the child’s birth. Since HIV
infection is a frequent cause of death among Caribbean
women of reproductive age [10], HIV antibody testing was
performed in orphaned and abandoned minors if maternal
serostatus was unavailable. If the patient was seropositive,
his/her guardian was oﬀered virologic testing. A case of HIV
infection acquired by MTCT was defined as an infant with a
positive HIV nucleic acid amplification test [11]. Infants who
had negative HIV nucleic acid amplification tests and had no
symptoms of HIV infection were considered uninfected, but
were followed until their HIV antibody tests were negative.
2.2. Prenatal and Infant pMTCT Practices. From 1999–2004,
in La Romana province, in the region that formerly had
the highest HIV prevalence in 2002 [12], nongovernmental
organizations provided prenatal, perinatal and neonatal
multidose zidovudine-containing regimens, with elective
cesarean delivery and exclusive formula feeding, to HIV-
infected mothers and their infants [6, 13]. During this
time period, all data for this paper were collected from
La Romana (Figure 1). Outside of La Romana, most HIV-
infected women who were diagnosed during pregnancy
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Figure 1: Perinatally HIV-Exposed Infants, by 34 Reporting centers,
Dominican Republic, 1999–2011 “La Romana”: nongovernmental
organization (NGO) located in La Romana, in southeastern
Dominican Republic, provides prenatal care to 81–101 pregnant
women living with HIV annually, approximately 30% of Haitian
origin, and 20% from bateyes (underserved sugarcane plantation
communities); virtually all (>97%) are low-income informally
employed or unemployed [6, 13]. The NGO provides comprehen-
sive care to approximately 1,300 persons living with HIV, of whom
130 are children. La Romana is a major sugar-producing area, with
100 s of bateyes for workers. It is also a major tourist attraction.
“Maternal Infant Hospital, SD”: public maternity hospital, located
in Santo Domingo (SD) East, in the southern coast of the
Dominican Republic [14], reports over 10,800 live births, at least
800 to women living with HIV. Most of the clients are low income,
and over 20% may be of Haitian origin. The hospital provides
comprehensive care to 90–101 children living with HIV. “National
Children’s Hospital, SD”: Public children’s hospital located in SD,
DR capital city, in the southern coast of the DR, reports >6,000
admissions per year, and evaluates 150–200 perinatally exposed
infants per year. Most of the clients are low-income, and at least
20% are referred to tertiary services in the Children’s Hospital
from other areas. The hospital provides comprehensive care to
over 400 children living with HIV. “General Hospital, Santiago”:
public general hospital located in the Northern city of Santiago
de los Caballeros, reports approximately 23,000 admissions per
year, of which 10,000 are obstetric, 90–120 of which are among
women living with HIV. Although it is located in one of the
more economically prosperous areas of the DR, it serves a diverse
population and many clients are from impoverished border areas.
The hospital provides comprehensive care to over 1,300 adults
living with HIV, and prenatal care services to over 100 women
living with HIV annually. “Pediatric Hospital, Santiago”: public
children’s hospital located in the Northern city of Santiago de los
Caballeros, reports over 3,000 admissions per year, and evaluates
50–60 perinatally exposed children per year. The hospital provides
comprehensive care to approximately 140 children living with HIV.
The other 29 centers that are represented in this population include
two community based, three faith-based, and two other NGOs, and
22 public hospitals in the eastern, border, central, and southwestern
provinces, including Elias Pina, El Seibo, and other low-healthcare-
access areas [12, 15, 16].
were oﬀered single-dose nevirapine at delivery, and exclusive
formula feeding for their infants, according to national
guidelines [17]. From 2004–2008, some women diagnosed
with HIV infection before or during pregnancy started or
continued HAART if they needed it for immunodeficiency;
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others received single-dose nevirapine or a zidovudine-
containingmultidose regimen [13]. In 2008, the DRministry
of health issued guidelines recommending maternal HAART
for pMTCT, whether or not the mother had evidence of
immunodeficiency (Protocol for use of combined antiretro-
viral therapy in pregnant women living with HIV/AIDS,
Ministry of Health, Santo Domingo, DR, October 2008).
These guidelines called for initiating zidovudine and lamivu-
dine combined with nevirapine if the woman’s CD4+ T-
lymphocyte count was less than 250 cells per mm3 [18]
or ritonavir-boosted lopinavir if the woman’s CD4+ T-
lymphocyte count was higher. HAART users with a docu-
mented quantitative HIV RNA concentration (“viral load”)
less than 1,000 viral particles/ml3 were advised to deliver
vaginally; non-HAART users and those with unknown or
higher viral loads were encouraged to undergo elective
cesarean delivery.
2.3. Laboratory Testing. Plasma specimens were obtained
at age one to 25 months from known perinatally exposed
and/or HIV-antibody-positive infants born from 1999–2005
for DNA polymerase chain reaction (PCR) qualitative or
quantitative HIV-1 “viral load” testing. If viral nucleic acid
was detected, testing was repeated. If the result was negative
and the sample had been obtained prior to six months of
age, the test was repeated at age of six months. From 2006–
2011, dried blood spots (DBS) obtained from perinatally
exposed and/or HIV-antibody-positive infants and children
aged one to 25months were collected according to previously
published procedures and tested for viral nucleic acid [19].
2.4. Data Abstraction, Processing and Analysis. Information
regarding maternal HIV diagnosis, prenatal antiretroviral
treatment, delivery, and infant antiretroviral treatment and
nutrition was obtained from maternal and infant medical
records from 1999 to 2005. Physicians and nurses providing
care for perinatally HIV-exposed infants queried the parents
or guardians about this information 2006–2011 and docu-
mented their responses on laboratory requisition forms for
HIV PCR testing on DBSs when the parent or guardian
consented to the infant’s HIV PCR test. No attempts were
made to verify the data obtained, beyond reviewing maternal
or infant records, if available. When guardians did not have
the information, and it was not found in requisitions or
records, values were coded as missing.
Data were entered into Excel databases, (one in La
Romana, and the other for the rest of the sites) and updated
with the DBS HIV test results when they were received. In
2012, the Excel databases were converted to Epi Info v3.5.1
for Windows (Centers for Disease Control and Prevention,
2008) files, the variables were harmonized, and the databases
were merged and analyzed [20].
HIV MTCT rates per 100 infants and children were
calculated for maternal and infant antiretroviral regimen,
delivery and infant nutrition characteristics, year and period
(pre- and post-HAART for pMTCT guidelines) of birth,
and by the various pMTCT strategies. Chi-square or Fisher’s
exact two-tailed tests were used to evaluate categorical
variables for statistical significance. The Kruskal-Wallis test
for two groups was used for continuous variables. Stratified
analyses were performed to control for confounding.
2.5. Prenatal and Infant Feeding Practices. Proportions of
women who attended prenatal care, had hospital deliver-
ies and breastfed were obtained from 2007 Demographic
and Health Survey (DHS) data [12]. Data on HIV in
bateyes (underserved sugarcane plantation communities)
were obtained from a DHS 2007 component [15]. Updates
on pMTCT strategies in 2003–2005, 2009, and HIV preva-
lence estimates, projections, and national prevention objec-
tives in 2009 were reviewed [14, 16, 21].
3. Results
3.1. Population. Data from 1,576 infants and children born
fromDecember 1, 1999 to December 31, 2011 were analyzed.
These included data collected in 34 centers from 1,274 infants
born from 1999–2008, and in 18 centers from 302 infants
born from January 1, 2009 to December 31, 2011 (Figure 1).
Age at specimen collection ranged from 20 days to 25months
(median = 3.0 months; mean = 4.7; s.d. = 3.9; mode = 2.0
months); 1,541 (97.8%) samples were collected before the
child was 15 months old.
3.2. Prenatal, Delivery, and Postpartum pMTCT Practices.
From 1999 to 2008, HIV infection was diagnosed during
the pregnancy in 48.4% mothers, prior to the pregnancy
in 21.7%, and during labor or within 72 hours of birth
in 5.7% and 5.2%, respectively (Table 1). Maternal HIV
infection was diagnosed after 72 hours and during the child’s
infancy or early childhood in 12.6%. In 6.3%, testing was
performed and maternal HIV infection was diagnosed at
other or unknown times. After publication of the national
guidelines recommending HAART for pMTCT (2009–2011),
the proportion diagnosed during labor and delivery rose and
the proportions diagnosed within 72 hours of birth and at
other or unknown times declined significantly. Otherwise,
the distribution did not change significantly from the 1999
to 2008 period.
Maternal antiretroviral use during pregnancy, labor, or
delivery rose significantly (Table 1). Women in the earlier
period were significantly more likely to receive a single-dose
nevirapine regimen than women who delivered from 2009
to 2011. Conversely, women who delivered from 2009 to
2011 were significantly more likely to receive HAART than
in 1999 to 2008. All 157 women who received HAART before
2009 had CD4+ T-lymphocyte counts less than 250 permm3.
The majority (57.6%) of women who delivered in 2009–2011
received HAART, and most of these HAART recipients had
CD4 counts higher than 250 and received ritonavir-boosted
lopinavir. Duration of nevirapine-containing HAART at
delivery (median = 286 days) was longer than the duration of
lopinavir-containing HAART (median = 104 days; P < .001);
mothers who used nevirapine-containingHAARTweremore
likely to have started it before pregnancy than those who
used lopinavir-containing HAART. Use of other multidose
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Table 1: Characteristics of maternal HIV diagnosis, maternal and infant antiretroviral use, mode of delivery and infant feeding, Dominican
Republic, 1999–2008, and 2009–2011.
Diagnosis and management
1999–2008 2009–2011
No. (%) No. (%)
N = 1,274 N = 302
Time of HIV diagnosis
Before pregnancy 277 (21.7) 77 (25.5)
During pregnancy 617 (48.4) 143 (47.4)
Labor/delivery 73 (5.7) 38 (12.6)∗
≤72 hours post-partum 66 (5.2) 5 (1.7)∗
After 72 hours 160 (12.6) 38 (12.6)
Unknown 81 (6.3) 1 (0.3)∗
Maternal antiretroviral use
Any 868 (68.1) 265 (87.7)∗
HAART, either 157 (12.3) 205 (67.9)∗
AZT + 3TC + NVP1 157 (12.3) 59 (19.5)
AZT-3TC-Lop2 — 146 (48.3)∗
Multidose AZT 19 (1.5) 0
Multidose AZT + 3TC 61 (4.8) —
Single dose NVP3 503 (39.5) 60 (19.5)∗
Received no ARVs 406 (31.9) 37 (12.2)∗
Unknown 121 (9.5) 0∗
Type of delivery
Vaginal 285 (22.4) 81 (26.8)
All Caesareans 882 (69.2) 199 (65.9)
Elective caesarian 882 (69.2) 152 (50.3)
Emergency caesarean — 47 (15.6)
Unknown 107 (8.4) 22 (7.3)
Infant nutrition
Formula only 972 (76.3) 260 (86.1)∗
Breast feeding only 67 (5.3) 4 (1.3)∗
Both 43 (3.4) 13 (4.2)
Unknown 192 (15.1) 25 (8.3)∗
Infant antiretrovirals (ARVs)
Started between 8–72 hours 782 (61.4) 184 (60.9)
Multidose AZT 81 (6.4) 126 (41.7)∗
Single-dose NVP only 701 (55.0) 58 (19.3)∗
Did not receive ARVs 219 (17.2) 74 (24.6)∗
Unknown 273 (21.4) 44 (14.5)∗
∗
P < .01 by time period.
1Zidovudine, lamivudine, nevirapine highly active antiretroviral therapy.
2Zidovudine, lamivudine, ritonavir-boosted lopinavir highly active antiretroviral therapy.
non-HAART regimens for one to 24 weeks was reported in
61 women who received combined zidovudine-lamivudine
and 19 who received zidovudine during the pregnancy and
caesarean delivery in the period 1999–2008; no multi-dose
antiretroviral regimens other than HAART were reported in
2009–2011 (Table 1).
Over 60% of infants in both periods were delivered
by caesarean section and were administered antiretrovirals
between 8 and 72 hours after birth; these proportions did
not vary significantly by period (Table 1). A single dose of
nevirapine was administered to most infants who received
antiretrovirals from 1999 to 2008, while most infants in
the 2009–2011 period who received antiretrovirals received
a multidose regimen (P < .01). The proportion who were
exclusively formula-fed rose and the proportion who were
exclusively breastfed declined significantly.
3.3. Perinatally Acquired HIV Infection. Overall, in both
periods combined, HIV infection was diagnosed in 154/1,576
(9.8%) of perinatally exposed infants and children. The
proportion infected declined from 11.1% (142/1,274) in
1999–2008 to 4.0% (12/302) in 2009–2011 (P < .001)
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(Table 2). MTCT varied in both periods by whether or not
mothers received any antiretrovirals during pregnancy or
delivery, and by type of antiretroviral regimen. MTCT rates
were similar for infants whose mothers received single-dose
nevirapine, regardless of when the nevirapine was given
in 1999–2008. The MTCT rate in infants whose mothers
received single-dose nevirapine was higher than in those
whose mothers received prenatal HAART in 1999–2008
and in 2009–2011 (6.4% versus 2.5% and 5.7% versus
2.9%, resp.) (Table 2). However, the diﬀerence was only
statistically significant when the two periods were combined;
9/331 [2.7%]) infants of mothers who received HAART
were infected, versus 35/601 (5.8%) infants of mothers who
received single-dose nevirapine (P = .03).
The MTCT rate among infants of mothers who received
HAART varied significantly by how long the mother had
received HAART at delivery. HAART duration was shorter
(median = 16.5 days) in mothers whose infants were infected
than in mothers whose infants were not infected (median
= 161 days; P = .003). In the 1999–2008 period, MTCT
rates varied considerably by type of delivery, ranging from
6.8% with cesarean delivery to 23.9% with vaginal delivery.
MTCT rates in the latter period were lower for both types of
delivery (2.5% and 7.5% in infants delivered by cesarean and
vaginally, resp.). MTCT rates also were higher and tended to
vary more by infant-feeding strategy in 1999–2008 than in
2009–2011.
MTCT rates varied from 5.0% and 6.1% among infants
receiving six weeks of zidovudine or single-dose nevirapine
within 72 hours of birth, respectively, to 9.4% among
infants who did not receive any antiretroviral in 1999–2008
(Table 2). In contrast, in 2009–2011, when most infants
received antiretrovirals, MTCT rates ranged from 2.4%
to 5.6% among infants receiving single-dose nevirapine
or six weeks of zidovudine, and the diﬀerences were not
significant. MTCT rates varied significantly in 1999–2008
from 8.1% in exclusively formula-fed infants to 37.3% in
exclusively breastfed infants. In the latter periods, only 6
infants received breast milk; MTCT rate in those who were
exclusively formula fed or receiving unknown nutrition
was 4.1% and 4.0%, significantly lower than in 1999–2008.
When the analysis was confined to infants whose mothers
had received HAART, were delivered by cesarean and had
exclusive formula feeding, the MTCT rate was 1.6% in 1999–
2008 and 2.3% in 2009–2011. Only 1 of 81 infants born in La
Romana in 2011 (1.2%) was infected.
MTCT rates varied significantly by center (Table 3); the
MTCT rate in the La Romana center was lower than in
other centers in both time periods, but the diﬀerence was
only significant in 1999–2008 (P < .001). The decline in
MTCT risk from 1999–2008 to 2009–2011 was from a higher
baseline, of greater magnitude, and statistically significant at
centers outside La Romana. The decline in the La Romana
center was not statistically significant. When controlled for
prenatal antiretroviral use and exclusive formula feeding, no
diﬀerences in MTCT rates between La Romana and other
centers were significant (Tables 2 and 3). Most of the declines
in MTCT and the diﬀerences by center (Table 3) were due to
higher use of maternal antiretrovirals and exclusive formula
feeding in La Romana in 1999–2008, and higher use of
maternal antiretrovirals and exclusive formula feeding in
2009–2011 in all centers.
3.4. Prenatal Screening, Delivery, and Infant Nutrition Prac-
tices in the DR. Prenatal care utilization in the DR was
estimated at greater than 95% in 2007, and varied from
96.6% in Elias Pin˜a to 99.6% in Santo Domingo and
from 95.1% in women who had never attended school
(uneducated) to 99.6% among high school graduates [13].
Almost all births (97.8%) of births were attended by a
health professional, ranging from 84% in Elias Pin˜a to
99.7% in Santo Domingo, and from 91.0% to 99.7% among
uneducated and high school graduates, respectively. The vast
majority (97.5%) of births occurred in hospitals (ranging
from 83.3% to 99.1% in Elias Pin˜a and Santo Domingo,
and from 89.2% to 98.7% among uneducated women and
high school graduates, resp.). The mean number of prenatal
visits was 6.6. Only 7.8% of infants aged 0–5 months were
exclusively breastfed [13]. In 2003–2005, in a survey of
sentinel sites, over 95% of women consented to HIV prenatal
testing; only 76% received their test results [21]. In one of
the largest DR centers, samples for rapid tests are collected,
stored, and performed at the end of the day; the pregnant
women were asked to return the next day or week for the
results [14]. HIV prevalence in pregnant women varied with
the highest prevalence in La Vega (8.4%), Mao (5.4%) and La
Romana (3.2%) [16].
Residents of bateyes (generally underserved persons,
many of Haitian origin), were surveyed [15]; 92% of women
who had a recent pregnancy had been tested for HIV during
the pregnancy, but only 58% received posttest counseling,
including their test results. HIV prevalence among female
residents in bateyes was higher (3.1%) than in the general
female DR population (0.8%) and varied from 3.1% among
20–24 year olds to 4.9% among 30–34 year olds, and was
highest (7.9%) among women aged 45–49 years old. HIV
prevalence in DR women varied by educational attainment,
from less than .3% in high school graduates to 3.7% in
uneducated women [12, 16]. HIV prevalence in the general
population varied geographically, with highest prevalence in
the northernmost border with Haiti (1.6%) and the eastern
sugar-growing region, where La Romana and most bateyes
are located (1.2%), and the lowest prevalence in the middle-
border region (.4%).
4. Discussion
The data in this study suggest that elimination of MTCT
in the DR is feasible and attainable. Encouraging signs
include the significant increases in proportion of women
who received antiretrovirals during their pregnancy, with
most of that increase being in HAART use in women without
severe immunodeficiency, and the proportion of infants
receiving exclusive formula feeding. These increases coincide
with and largely explain the decrease in MTCT observed
in the years since the publication of guidelines for use of
HAART for pMTCT. They also coincide with some national
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Table 2: HIV mother-to-child transmission risk in the 1999–2008 and 2009–2011 periods, by prenatal antiretroviral, delivery route, and
infant feeding prevention strategies, Dominican Republic.
All perinatally exposed 142/1,274 (11.1%) 12/302 (4.0%)∗
Any maternal antiretrovirals 54/861 (6.3) 10/267 (3.7)
HAART1 all 4/157 (2.5) 5/174 (2.9)
AZT + 3TC + NVP2 4/157 (2.5) 0/59
AZT + 3TC + Lopinavir/r3 — 5/115 (4.3)
Non-HAART multidose
4/80 (5.0) —
AZT-containing regimen
Single-dose NVP ALL 32/506 (6.3) 3/60 (5.0)
8 hours precaesarean 25/395 (6.3) 0/2
Labor onset 5/78 (6.4) —
At delivery 2/30 (6.7) —
Unspecified — 3/58 (5.2)
Unknown 14/211 (11.6) 2/30 (6.7)
None 88/413 (21.3)† 2/35 (5.7)∗
Delivery
Vaginal 68/285 (23.9)† 6/80 (7.5)∗
Caesarean 60/882 (6.8) 5/199 (2.5)∗
Unknown 14/107 (13.1) 1/23 (4.3)∗
Infant antiretrovirals
Single-dose Nevirapine (SD NVP) 48/782 (6.1) 1/41 (2.4)
SD-NVP after 72 hours 1/13 (7.6) —
Zidovudine for six weeks 7/139 (5.0) 7/126 (5.6)
Unknown/other/none 32/340 (9.4)† 4/135 (3.0)
Infant feeding
Breast fed only 25/67 (37.3) 0/2
Mixed 16/43 (37.2) 0/4
Formula only 79/972 (8.1)† 11/271 (4.1)∗
Unknown 22/192 (11.5) 1/25 (4.0)∗
∗
P < .05, comparison by time period, 1999–2008 versus 2009–2011.
†P < .01 within period, by strategy.
1Highly active antiretroviral therapy.
2AZT-3TC-NVP: zidovudine, lamivudine, nevirapine.
3AZT-3TC-Lop/r: zidovudine, lamivudine, lopinavir (ritonavir boosted).
trends that suggest a possible decline in HIV prevalence and
unsafe sex practices, and documented increase in HAART
use nationwide [1, 12, 16, 22, 23].
These encouraging findings contrast with persistent
problems implementing the fundamentals of eﬀective
pMTCT, particularly informing pregnant women of their
HIV status, and linking them to care and HAART. It is clear
that all of the components of the “cascade” needed forMTCT
elimination are present in the DR. These include high use of
prenatal care and institutional delivery by trained personnel;
high acceptability of prenatal HIV testing, formula feeding,
and prenatal, perinatal, and infant antiretroviral use, and
legislation that oﬀers some protection, though modest and
with draconian components, for people living with HIV
[24, 25].
Yet the “weak links” in this system are unfortunately at
points where they threaten the many strengths of the pro-
gram. The principal weak links include the high proportion
of women tested in prenatal care who do not receive their
results. According to national guidelines, prenatal HIV test-
ing in the DR is to be performed using rapid antibody tests;
results of samples that test positive are then confirmed with
another rapid test that uses a diﬀerent principle, according
to WHO guidelines [26], allowing infected pregnant women
to receive at least presumptive, if not confirmed, positive test
results in the same visit in which the sample for testing is
obtained. Yet according to an observational study and a case
report in some centers, samples were stored as they were
collected and rapid tests run once a day; women were asked
to return for their results, and posttest counseling sometimes
consisted of reporting that the test “needs to be repeated”
without clarifying that it was a presumptive positive test,
leading to women delivering without an HIV diagnosis,
MTCT, and maternal and infant HIV progression and death
[14, 27, 28].
Another potential weakness in the cascade is the linkage
to specialized care for an expedited CD4+ T-lymphocyte
count to determine which HAART and other treatments are
Infectious Diseases in Obstetrics and Gynecology 7
Table 3: Mother to child transmission (MTCT) rates by period (before recommendation of highly active antiretroviral therapy (HAART) for
prevention of MTCT (1999–2008), and after (2009–2011) by center (La Romana center versus others) and prevention strategies, Dominican
Republic.
1999–2008 2009–2011
MTCT rate P MTCT rate P
No. of infected/total (%) No. of infected/total (%)
La Romana 20/301 (6.6)
<.001
8/212 (3.8)
.9
Other centers 122/973 (12.5) 4/90 (4.9)∗
Any prenatal antiretroviral use
La Romana 6/179 (3.3)
.16
8/187 (4.3)
.8
Other centers 34/561 (6.1) 2/78 (2.6)
Any prenatal antiretroviral use, formula only
La Romana 6/149 (4.0)
.28
8/183 (4.4)
.7
Other centers 35/547 (6.4) 1/53 (1.9)
No prenatal antiretroviral use
La Romana 13/114 (11.4)
.002
0/25 (0)
.036
Other centers 75/299 (25.1) 2/12 (16.7)
No prenatal antiretroviral use, formula only
La Romana 4/31 (12.9)
.51
0/25 (0)
.15
Other centers 26/146 (17.8) 2/10 (20)
∗
Diﬀerence between 1999–2008 period and 2009–2011 period P < .05.
indicated for the mother’s health and pMTCT. In at least
one center, in La Romana, this is facilitated by having the
counselor (usually a woman living with HIV herself [21]),
contact an HIV comprehensive care unit to have staﬀ from
that unit personally meet with and expedite the pregnant
woman’s linkage to care. Models of this type in the DR have
demonstrated the feasibility of eﬀective linkage to care for
pMTCT and maternal health. However, in centers whose
referral process consists of asking the women to schedule
an appointment with a specialized clinic, many women will
not receive HAART, even if they continue prenatal care.
Moreover, despite a high level of utilization of prenatal
care and hospital delivery, the populations least likely to
access these services include the most HIV-aﬀected [12,
15]; alternative methods of reaching these populations are
essential.
The dependence on ritonavir-boosted lopinavir (instead
of efavirenz, as recommended by theWHO [29]) for HAART
for women who are not severely immunesuppressed because
of probably exaggerated concerns about its teratogenicity
may limit their antiretroviral options in the future, and
incurs a prohibitive cost compared to efavirenz [6]. Finally,
although there is growing acceptance of the rights of people
living with HIV, stigma, and discrimination continue to
aﬀect women with HIV in the DR [30, 31]. These women
may also be unaware of their right to HAART at no cost
[24, 25]. In the past, some HIV-infected women who did
not receive their results found that they were given instead
to employers, landlords or medical personnel; they were
denied employment, housing, and elective medical services,
including cesarean delivery for pMTCT [30, 31]. The new law
criminalizes even protected sex with an uninfected partner;
thus, some DR women who know or suspect their status may
consider the risks of testing to be unacceptably high [24].
This study has several strengths. It contains data on by
far the largest number of HIV perinatally exposed infants
of any study conducted in the DR. A considerable amount
of data was collected on infants from a large number of
diverse centers distributed widely throughout the country.
However, this analysis has several problems that limit its
generalizability in characterizing MTCT in the DR. First,
surveillance for perinatal HIV exposure that depends on
testing living infants and children is susceptible to the
important survival bias related to the high mortality (up
to 30%) of untreated perinatally acquired HIV infection
in the first two years of life [28]. Also, these data do
not represent the majority of cases of perinatal exposure
in the DR; the estimates of HIV prevalence in some DR
pregnant and childbearing populations, and the numbers
of HIV-infected women delivering each year (notably in
La Romana and some sentinel surveillance hospitals) have
been confirmed by several studies [13, 17], enabling reliable
estimates of the proportion of perinatally exposed infants
that are returned for virologic testing. At the national level,
the estimated number of women with HIV who deliver
annually (at least 1,400 to over 5,700) is much higher than
the number of infants tested. This study represents at best a
small proportion of DR perinatally exposed infants [6, 13,
16, 17, 21], and greatly over represents the centers (the NGO
in La Romana and one of the public Maternity Hospitals in
Santo Domingo) [14] with the best outcomes.
Despite these limitations, this analysis represents the
first glimpse of the impact of the historic recommendations
for HAART use for pMTCT with a large, representative
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database. It suggests that MTCT elimination is possible with
current tools; indeed, some of the DR’s 2012 benchmarks
were achieved in 2011 [16]. Barriers to elimination are
related to failures to ensure that HIV-infected women are
informed of their status and linked to care. Structural
barriers limit healthcare access for the DR’s most HIV-
aﬀected, most marginalized populations. Surmounting these
barriers requires innovative strategies to close the gaps in this
promising model [32].
Acknowledgments
The authors gratefully acknowledge the contributions of Jose´
Ledesma, M.D., Ana Gloria Bido, M.D., and David Martin,
M.D., of the Clinton Foundation HIV/AIDS Initiative, Santo
Domingo, who supported all aspects of the use of dried
blood spots for collection of specimens for virologic testing,
in collaboration with the Direccio´n General de Control
de Infecciones de Transmisio´n Sexual y SIDA; Susan A.
Fiscus, Ph.D., Mark Turner, and the staﬀ at the University
of North Carolina Retrovirology Laboratory, Chapel Hill,
North Carolina; the Virology Laboratory of the National
Institute of Communicable Diseases in Johannesburg, South
Africa, and the National Virology Laboratory for performing
the virologic testing; the staﬀ of the 20 participating HIV
MTCT programs, including counselors, physicians, nursing,
and laboratory staﬀ; themothers and guardians of the infants
who consented to virologic testing and the peer-community-
based home visitors and caregivers who promoted adherence
to prenatal and infant antiretroviral and safe artificial
formula use.
References
[1] Joint United Nations Programme on HIV/AIDS, UNAIDS
World AIDS Day Report, http://www.unaids.org/en/media/
unaids/contentassets/documents/unaidspublication/2011/JC-
2216 WorldAIDSday report 2011 en.pdf, 2011.
[2] World Health Organization, “Progress report 2011: global
HIV/AIDS response,” Tech. Rep., WHO, Geneva, Switzerland,
2011.
[3] S. K. Whitmore, A. W. Taylor, L. Espinoza, R. L. Shouse, M.
A. Lampe, and S. Nesheim, “Correlates of mother-to-child
transmission of HIV in the United States and Puerto Rico,”
Pediatrics, vol. 129, no. 1, pp. e74–e81, 2012.
[4] C. L. Townsend, M. Cortina-Borja, C. S. Peckham, A. De
Ruiter, H. Lyall, and P. A. Tookey, “Low rates of mother-
to-child transmission of HIV following eﬀective pregnancy
interventions in the United Kingdom and Ireland, 2000-2006,”
AIDS, vol. 22, no. 8, pp. 973–981, 2008.
[5] S. Tariq, C. L. Townsend, M. Cortina-Borja et al., “Use of
zidovudine-sparing HAART in pregnant HIV-infected women
in Europe: 2000–2009,” Journal of Acquired Immune Deficiency
Syndromes, vol. 57, no. 4, pp. 326–333, 2011.
[6] N. C. Schmidt, J. Roman-Pouriet, A. D. Fernandez, C. M.
Beck-Sague´, J. Leonardo-Guerrero, and S. W. Nicholas, “Costs
and benefits of multidrug, multidose antiretroviral therapy
for prevention of mother-to-child transmission of HIV in the
Dominican Republic,” International Journal of Gynecology &
Obstetrics, vol. 116, no. 3, pp. 219–222, 2012.
[7] B. Robberstad and B. Evjen-Olsen, “Preventing mother to
child transmission of HIV with highly active antiretroviral
treatment in Tanzania-a prospective cost-eﬀectiveness study,”
Journal of Acquired Immune Deficiency Syndromes, vol. 55, no.
3, pp. 397–403, 2010.
[8] S. Orlando, M. C. Marazzi, S. Mancinelli et al., “Cost-
eﬀectiveness of using HAART in prevention of mother-to-
child transmission in the DREAM-project Malawi,” Journal of
Acquired Immune Deficiency Syndromes, vol. 55, no. 5, pp. 631–
634, 2010.
[9] Joint United Nations Program on HIV/AIDS (UNAIDS) and
World Health Organization (WHO), AIDS Epidemic Update
2009, World Health Organization, Geneva, Switzerland, 2009.
[10] United States Agency for International Development, HIV/
AIDS Health profile for the Caribbean Region, http://transi-
tion.usaid.gov/our work/global health/aids/Countries/lac/ca-
ribbean profile.pdf, Pages 1–6, 2012.
[11] Centers for Disease Control and Prevention, “Revised surveil-
lance case definitions for HIV infection among adults, adoles-
cents, and children aged < 18 months and for HIV infection
and AIDS among children aged 18 months to < 13 years—
United States, 2008,” Morbidity and Mortality Weekly Report,
vol. 57, no. 10, pp. 5–8, 2008.
[12] Centro de Estudios Sociales and Demogra´ficos (CESDEM)
y Macro International Inc, Encuesta Demogra´fica y de Salud
2007. (Demographic and Health Survey, 2007, CESDEM y
Macro International Inc., Santo Domingo, Repu´blica Domini-
cana, 2008.
[13] J. Roma´n-Poueriet, A. D. Fernandez, C. M. Beck-Sague´ et al.,
“HIV infection and prevention of mother-to-child transmis-
sion in childbearing women: La Romana, Dominican Repub-
lic, 2002–2006,” Revista Panamericana de Salud Publica/Pan
American Journal of Public Health, vol. 26, no. 4, pp. 315–323,
2009.
[14] M. Connolly, C. Bautista-Soriano, and A. Castro, “Utilizacio´n
formulario de la Historia Clı´nica Perinatal y Neonatal
CLAP/OPS-OMS. (Use of the Clinical Perinatal and Neona-
tal History Forms CLAP/PAHO-WHO) Publicacio´n Bol.,”
CENISMI, vol. 19, no. 3, pp. 17–23, 2009.
[15] CESDEM and Macro International Inc., Encuesta Socioe-
mogra´fica y sobre VIH/SIDA en los Bateyes Estatales de la
Repu´blica Dominicana 2007, CESDEM y Macro International
Inc., Santo Domingo, Dominican Republic, 2008.
[16] Consejo Presidencial del SIDA (COPRESIDA), “Ministerio de
Salud Pu´blica y Asistencia Social Informe de estimaciones y
proyecciones de prevalencia de carga de enfermedad an˜o
2009,” http://copresida.gob.do/.../Informe Estimaciones 2009,
2011.
[17] E. Perez-Then, R. Pen˜a, M. Tavarez-Rojas et al., “Preventing
mother-to-child HIV transmission in a developing country:
the Dominican Republic experience,” Journal of Acquired
Immune Deficiency Syndromes, vol. 34, no. 5, pp. 506–511,
2003.
[18] K. V. Shepard, “Clarification of risk factors for severe,
life-threatening and fatal hepatotoxicity with VIRAMUNE
(nevirapine),” 2004, http://www.fda.gov/Safety/MedWatch/
SafetyInformation/SafetyAlertsforHumanMedicalProducts/
ucm166533.htm?utm campaign=Google2&utm source=fda-
Search&utm medium=website&utm term=cd4nevirapine&
utm content=1&utm source=fdaSearch&utm medium=web-
site&utm term=cd4nevirapine&utm content=1, 2012.
[19] G. G. Sherman, G. Stevens, S. A. Jones, P. Horsfield, and W. S.
Stevens, “Dried blood spots improve access to HIV diagnosis
Infectious Diseases in Obstetrics and Gynecology 9
and care for infants in low-resource settings,” Journal of Acqui-
red Immune Deficiency Syndromes, vol. 38, no. 5, pp. 615–617,
2005.
[20] A. G. Dean, K. M. Sullivan, and M. M. Soe, “Epi Info and
OpenEpi in epidemiology and clinical medicine. Health appli-
cations of free software,” http://www.epiinformatics.com/,
2012.
[21] E. Perez-Then, C. Bautista Soriano, R. Espinal et al., Cen-
tro Nacional de Investigaciones de Salud Materno-Infantil
(CENISMI). Consolidation of strategies for reduction of HIV
MTCT in the Dominican Republic (CENISMI-Glaser Project).
CENISMI, Santo Domingo, DR.
[22] P. Rojas, R. Malow, B. Ruﬃn, E. M. Rothe, and R. Rosenberg,
“The HIV/AIDS epidemic in the Dominican Republic: key
contributing factors,” Journal of the International Association
of Physicians in AIDS Care, vol. 10, no. 5, pp. 306–315, 2011.
[23] D. T. Halperin, E. A. De Moya, E. Pe´rez-Then, G. Pappas,
and J. M. Garcia Calleja, “Understanding the HIV epidemic
in the Dominican Republic: a prevention success story in
the Caribbean?” Journal of Acquired Immune Deficiency Syn-
dromes, vol. 51, no. 1, pp. S52–S59, 2009.
[24] L. Fernandez, Ley 135-11 VIH/SIDA, Promulgated by the Pre-
sident, Santo Domingo, Dominican Republic, 2011.
[25] F. A. Cuello Camilo, “Statement by H. E. Ambassador Fred-
erico Alberto Cuello CamiloRepresentative of the Dominican
Republic to the United Nations,” in Proceedings of the High
Level Meeting of VIH/SIDA, 2012, http://www.un.org/en/ga/
aidsmeeting2011/pdf/dominican%20rep.pdf.
[26] World Health Organization, Rapid HIV Tests. 2004. Guidelines
for Use in HIV Testing and Counselling Services in Resource-
Constrained Settings, WHO, Geneva, Switzerland.
[27] A. Koppel, J. Leonardo-Guerrero, S. Rives, N. Paniagua-Torres,
C. Sparrow, and C. M. Beck-Sague´, “Immune reconstitution
inflammatory syndrome due to Mycobacterium bovis bacillus
Calmette-Gue´rin in infants receiving highly active antiretro-
viral therapy: a call for universal perinatal rapid HIV testing
prior to administration of BCG immunization of neonates,”
Journal of Tropical Pediatrics, vol. 56, no. 4, Article ID fmp115,
pp. 280–283, 2009.
[28] M. J. Mayaux, M. Burgard, J. P. Teglas et al., “Neonatal
characteristics in rapidly progressive perinatally acquired
HIV-1 disease,” Journal of the American Medical Association,
vol. 275, no. 8, pp. 606–610, 1996.
[29] World Health Organization, “Antiretroviral drugs for treating
pregnant women and preventing HIV infection in infants:
recommendations for public health approaches,” http://www
.who.int/hiv/pub/guidelines/pmtctguidelines3.pdf, 2012.
[30] Ca´ceres Uren˜a FI. Repu´blica Dominicana. Estigma y discri-
minacio´n en personas que viven con el VIH, http://www.sti-
gmaindex.org/download.php?id=44, 2012.
[31] M. Møllmann, A Test of Inequality: Discrimination against
women living with HIV in the Dominican Republic. Human
Rights Watch, http://www.hrw.org/sites/default/files/reports/
dr0704.pdf, 16, 2004.
[32] S. W. Nicholas, “Towards the elimination of pediatric HIV/
AIDS in New York State,” Journal of Public HealthManagement
and Practice, vol. 16, no. 6, pp. 509–511, 2010.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
The Scientific 
World Journal
International Journal of
Endocrinology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
ISRN 
Anesthesiology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Oncology
Journal of
Volume 2013
PPAR
Resea rch
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Allergy
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Obesity
Journal of
ISRN 
Addiction
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Computational and 
Mathematical Methods 
in Medicine
ISRN 
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Clinical &
Developmental
Immunology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Biomarkers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
MEDIATORS
INFLAMMATION
of
